Table 2.
Results of multivariate analysis for the selected 2241 pairs
| Endpoints | Variable | HR (95% CI) | P value a |
|---|---|---|---|
| DFS | Gender, female vs. male | 0.799 (0.681–0.937) | 0.006 |
| Age, > 44 vs. ≤ 44y | 1.191 (1.041–1.362) | 0.011 | |
| LDH; > 245 vs. ≤ 245 U/L | 1.596 (1.298–1.962) | < 0.001 | |
| T category; T3–4 vs. T1–2 | 1.283 (1.043–1.578) | 0.018 | |
| N category, N2–3 vs. N0–1 | 1.742 (1.506–2.015) | < 0.001 | |
| Overall stage, IVA vs. III | 1.867 (1.632–2.136) | < 0.001 | |
| Treatment, IC + CCRT vs. CCRT | 0.955 (0.837–1.090) | 0.494 | |
| OS | Gender; female vs. male | 0.700 (0.562–0.871) | 0.001 |
| Age, > 44 vs. ≤ 44y | 1.479 (1.238–1.768) | < 0.001 | |
| LDH; > 245 vs. ≤ 245 U/L | 1.734 (1.343–2.238) | < 0.001 | |
| N category, N2–3 vs. N0–1 | 1.922 (1.589–2.323) | < 0.001 | |
| Overall stage, IVA vs. III | 2.140 (1.795–2.550) | < 0.001 | |
| Treatment, IC + CCRT vs. CCRT | 0.894 (0.752–1.063) | 0.207 | |
| DMFS | Gender; female vs. male | 0.758 (0.616–0.932) | 0.009 |
| LDH; > 245 vs. ≤ 245 U/L | 1.938 (1.519–2.473) | < 0.001 | |
| N category, N2–3 vs. N0–1 | 1.959 (1.649–2.327) | < 0.001 | |
| Overall stage, IVA vs. III | 1.989 (1.678–2.357) | < 0.001 | |
| Treatment, IC + CCRT vs. CCRT | 0.926 (0.782–1.096) | 0.369 | |
| LRRFS | Smoking, yes vs. no | 1.263 (1.024–1.557) | 0.029 |
| Age, > 44 vs. ≤ 44y | 1.345 (1.088–1.662) | 0.006 | |
| T category, T3–4 vs. T1–2 | 1.494 (1.062–2.103) | 0.021 | |
| N category; N3 vs. N2 | 1.624 (1.297–2.033) | < 0.001 | |
| Overall stage, IVA vs. III | 1.654 (1.341–2.039) | < 0.001 | |
| Treatment, IC + CCRT vs. CCRT | 1.114 (0.906–1.369) | 0.306 |
Abbreviations: DFS disease-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, HR hazard ratio, CI confidence interval, IC induction chemotherapy, CCRT concurrent chemoradiotherapy, LDH lactate dehydrogenase
aP-values were calculated using an adjusted Cox proportional hazards model with backward elimination and the following variables were included: gender (female vs. male), age (> 44y vs. ≤ 44y), smoking (yes vs. no), drinking (yes vs. no), family history of cancer (yes vs. no), LDH (> 245 vs. ≤ 245 U/L), T category (T3–4 vs. T1–2), N category (N2–3 vs. N0–1), overall stage (IVA vs. III) and treatment (IC + CCRT vs. CCRT)